195 related articles for article (PubMed ID: 31434701)
1. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements.
Tanasi I; Ba I; Sirvent N; Braun T; Cuccuini W; Ballerini P; Duployez N; Tanguy-Schmidt A; Tamburini J; Maury S; Doré E; Himberlin C; Duclos C; Chevallier P; Rousselot P; Bonifacio M; Cavé H; Baruchel A; Dombret H; Soulier J; Landman-Parker J; Boissel N; Clappier E
Blood; 2019 Oct; 134(16):1351-1355. PubMed ID: 31434701
[No Abstract] [Full Text] [Related]
2. SFPQ-ABL1-positive B-cell precursor acute lymphoblastic leukemias.
Biloglav A; Olsson-Arvidsson L; Theander J; Behrendtz M; Castor A; Johansson B
Genes Chromosomes Cancer; 2020 Sep; 59(9):540-543. PubMed ID: 32306475
[TBL] [Abstract][Full Text] [Related]
3. Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: a perspective of the SEPT9-ABL1 fusion protein.
Hu T; Ciccarelli BT
Leuk Res; 2014 Dec; 38(12):1399-400. PubMed ID: 25449686
[No Abstract] [Full Text] [Related]
4. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion.
Moorman AV; Schwab C; Winterman E; Hancock J; Castleton A; Cummins M; Gibson B; Goulden N; Kearns P; James B; Kirkwood AA; Lancaster D; Madi M; McMillan A; Motwani J; Norton A; O'Marcaigh A; Patrick K; Bhatnagar N; Qureshi A; Richardson D; Stokley S; Taylor G; van Delft FW; Moppett J; Harrison CJ; Samarasinghe S; Vora A
Br J Haematol; 2020 Dec; 191(5):844-851. PubMed ID: 32926422
[TBL] [Abstract][Full Text] [Related]
5. TKIs may be option for Ph-like ALL.
Cancer Discov; 2014 Dec; 4(12):1359-60. PubMed ID: 25477088
[TBL] [Abstract][Full Text] [Related]
6. t(1;9)(p34;q34)/SFPQ-ABL1 Fusion in a Patient with Ph-Like Common B-Cell Acute Lymphoblastic Leukemia.
Sheng G; Zeng Z; Pan J; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
Acta Haematol; 2017; 137(1):40-43. PubMed ID: 27894117
[No Abstract] [Full Text] [Related]
7. Philadelphia-like acute lymphoblastic leukemia: diagnostic dilemma and management perspectives.
Kotb A; El Fakih R; Hanbali A; Hawsawi Y; Alfraih F; Hashmi S; Aljurf M
Exp Hematol; 2018 Nov; 67():1-9. PubMed ID: 30075295
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with
Frech M; Jehn LB; Stabla K; Mielke S; Steffen B; Einsele H; Metzelder SK; Neubauer A
Haematologica; 2017 Apr; 102(4):e160-e162. PubMed ID: 28057740
[No Abstract] [Full Text] [Related]
9. Reaping the benefits of recent advances for adults with acute lymphoblastic leukemia.
Brown PA; Alvarnas JC
J Natl Compr Canc Netw; 2012 Jul; 10(7):800-1. PubMed ID: 22773795
[No Abstract] [Full Text] [Related]
10. ABL1 rearrangements in T-cell acute lymphoblastic leukemia.
Hagemeijer A; Graux C
Genes Chromosomes Cancer; 2010 Apr; 49(4):299-308. PubMed ID: 20073070
[TBL] [Abstract][Full Text] [Related]
11. Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Swords R; Alvarado Y; Giles F
Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 3():S113-9. PubMed ID: 17382020
[TBL] [Abstract][Full Text] [Related]
12. NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.
Duployez N; Grzych G; Ducourneau B; Alarcon Fuentes M; Grardel N; Boyer T; Abou Chahla W; Bruno B; Nelken B; Clappier E; Preudhomme C
Haematologica; 2016 Apr; 101(4):e133-4. PubMed ID: 26681761
[No Abstract] [Full Text] [Related]
13.
Byun JM; Koh Y; Shin DY; Kim I; Yoon SS; Lee JO; Bang SM; Kim KH; Jung SH; Lee WS; Park Y; Jang JH; Han JJ; Yhim HY; Kim DS; Lee YJ; Lee H; Choi YS; Lee S;
Haematologica; 2017 May; 102(5):e187-e190. PubMed ID: 28082339
[No Abstract] [Full Text] [Related]
14. BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well?
Andolina JR
Acta Haematol; 2015; 134(2):69-70. PubMed ID: 25895547
[No Abstract] [Full Text] [Related]
15. Molecular cytogenetic analysis of gene rearrangements in childhood acute lymphoblastic leukemia.
Woo HY; Kim DW; Park H; Seong KW; Koo HH; Kim SH
J Korean Med Sci; 2005 Feb; 20(1):36-41. PubMed ID: 15716599
[TBL] [Abstract][Full Text] [Related]
16. SNX2-ABL1-positive acute lymphoblastic leukemia possibly has a poor prognosis.
Mu Q; Guo L; Hu Y; Sheng L; Zhang Y; Wu N; Chen Y; Shi C; Shi S; Wu Y; Ouyang G
Leuk Lymphoma; 2017 Sep; 58(9):1-3. PubMed ID: 28278724
[No Abstract] [Full Text] [Related]
17. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.
Boer JM; Koenders JE; van der Holt B; Exalto C; Sanders MA; Cornelissen JJ; Valk PJ; den Boer ML; Rijneveld AW
Haematologica; 2015 Jul; 100(7):e261-4. PubMed ID: 25769542
[No Abstract] [Full Text] [Related]
18. Why and how to treat Ph-like ALL?
Roberts KG
Best Pract Res Clin Haematol; 2018 Dec; 31(4):351-356. PubMed ID: 30466746
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
Leoni V; Biondi A
Haematologica; 2015 Mar; 100(3):295-9. PubMed ID: 25740105
[No Abstract] [Full Text] [Related]
20. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
